Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results...
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine Clinical study in children 2-11 years of age follows the recent EMA and WHO...
Bavarian Nordic Upgrades its Financial Guidance for 2024 COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s...
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September...
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines Contract will further strengthen the U.S, bulk vaccine inventory and...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents...
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism...
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine First mpox vaccine to obtain prequalification by the WHOApproval will help accelerate access to the vaccine for all African countries...
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation COPENHAGEN, Denmark, September 12, 2024 – Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN®, the only...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such COPENHAGEN, Denmark...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
